

# Differential Regulation of Primitive Myelopoiesis in the Zebrafish by Spi-1/Pu.1 and C/ebp1

Fengyun Su,<sup>1</sup> Marianne A. Juarez,<sup>1</sup> Christopher L. Cooke,<sup>1</sup> Lisa LaPointe,<sup>1</sup> Jordan A. Shavit,<sup>2</sup> Jennifer S. Yamaoka,<sup>2</sup> and Susan E. Lyons<sup>1</sup>

## Abstract

The zebrafish has become a powerful tool for analysis of vertebrate hematopoiesis. Zebrafish, unlike mammals, have a robust primitive myeloid pathway that generates both granulocytes and macrophages. It is not clear how this unique primitive myeloid pathway relates to mammalian definitive hematopoiesis. In this study, we show that the two myeloid subsets can be distinguished using RNA *in situ* hybridization. Using a morpholino-antisense gene knockdown approach, we have characterized the hematopoietic defects resulting from knockdown of the myeloid transcription factor gene *pu.1* and the unique zebrafish gene *c/ebp1*. Severe reduction of *pu.1* resulted in complete loss of primitive macrophage development, with effects on granulocyte development only with maximal knockdown. Reduction of *c/ebp1* did not ablate initial macrophage or granulocyte development, but resulted in loss of expression of the secondary granule gene *lys C*. These data reveal strong functional conservation of *pu.1* between zebrafish primitive myelopoiesis and mammalian definitive myelopoiesis. Further, these results are consistent with a conserved role between *c/ebp1* and mammalian *C/EBPE*, whose ortholog in zebrafish has not been identified. These studies validate the examination of zebrafish primitive myeloid development as a model for human myelopoiesis, and form a framework for identification and analysis of myeloid mutants.

## Introduction

**I**N MAMMALS, MYELOPOIESIS OCCURS during definitive hematopoiesis, through progressive commitment and differentiation steps from pluripotent hematopoietic stem cells to common myeloid progenitors that ultimately generate terminally differentiated erythroid, granulocyte, and macrophage/monocyte lineages. The genes that direct this process, including *scl*, *spi-1/pu.1* (hereafter called *pu.1*), *c/ebps*, and *gata1*, have been shown to play important roles not only in normal hematopoiesis but also in leukemogenesis.<sup>1–5</sup>

Zebrafish have become a powerful vertebrate model for analyses of hematopoiesis. Due to

the easy visibility of erythroid cells, over 26 hematopoietic mutants with abnormalities in erythroid populations have been identified.<sup>6</sup> The cloning of the genes mutated in these defects has identified both known and novel genes required for stem cell development, and development and/or maintenance of the erythroid lineage.<sup>7,8</sup> In contrast to the early hematopoietic screens that successfully identified alterations in erythropoiesis, mutagenesis screens to analyze myeloid deficiencies are in the early stages. The ability to design directed screens for myeloid defects requires a better understanding of normal myelopoiesis in the zebrafish.

Zebrafish develop both macrophages and granulocytes during primitive hematopoiesis,<sup>9–11</sup>

<sup>1</sup>Division of Hematology–Oncology and Cellular and Molecular Biology Program, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.

<sup>2</sup>HHMI and Life Sciences Institute, University of Michigan, Ann Arbor, Michigan.

while mammals generate largely erythroid cells, with a small number of primitive macrophages and no granulocytes, during primitive hematopoiesis.<sup>9–12</sup> Due to the ease of examining early events in the zebrafish, primitive myelopoiesis is being used in most screens to assess myelopoiesis, although the parallels that can be drawn between primitive myelopoiesis in zebrafish and definitive myelopoiesis in mammals are not known.

In the zebrafish, early markers of hematopoiesis are first evident by the 1–3 somite stage or 11 hours postfertilization (hpf) in two regions, the anterior lateral mesoderm (ALM) region near the head and the posterior lateral mesoderm (PLM), which later forms the intermediate cell mass (ICM).<sup>13</sup> Erythroid development takes place in the PLM/ICM, while macrophages develop from the ALM<sup>10</sup> and granulocytes may develop from the ALM and PLM.<sup>9,11</sup>

Transcription factors essential for myeloid development in mammals include PU.1 and a number of C/EBP family members. PU.1 is an Ets-family transcription factor known to be essential for macrophage and B lymphoid development and some aspects of granulocyte differentiation in mammals.<sup>14,15</sup> The C/EBP family of transcription factors includes several members involved in hematopoietic development. Orthologs of C/ebp $\alpha$  and C/ebp $\beta$  have been identified in the zebrafish.<sup>16</sup> Interestingly, an ortholog for C/ebp $\epsilon$ , required for terminal maturation of granulocytes and expression of secondary granule proteins in mammals, has not been identified in the zebrafish. However, another C/ebp family member, C/ebp1, was identified in zebrafish and is expressed specifically in myeloid cells.<sup>17</sup> The functional role of C/ebp1 in myeloid development has not yet been explored. Here we characterize the myeloid subsets present during primitive hematopoiesis and examine the functional roles of Pu.1 and C/ebp1 through a morpholino (MO)-based knockdown approach.

## Results

### *Two myeloid subsets can be distinguished in primitive zebrafish hematopoiesis*


To characterize the myeloid cell populations present in zebrafish embryos, whole-mount

embryos were examined by double RNA *in situ* hybridizations using the myeloid-specific markers *l-plastin* (*lcp/l-pl*),<sup>10</sup> *myeloperoxidase* (*mpo*),<sup>9</sup> *lysozyme C* (*lys C*),<sup>18</sup> *macrophage colony-stimulating factor receptor* (*csf1r/c-fms*),<sup>19,20</sup> and *CCAAT/enhancer binding protein 1* (*c/ebp1*).<sup>17</sup>

Previous work correlated the appearance of *l-pl* expression with regions in which macrophages were visualized in live embryos.<sup>10,20</sup> Further, *l-pl* has been shown to be coexpressed in at least a subset of cells expressing *c/ebp1*<sup>17</sup> and *lys C*,<sup>18</sup> while the majority of *mpo*-expressing cells were found to be distinct from *l-pl*.<sup>9</sup> However, further studies to distinguish clearly amongst these multiple subsets have not been performed.

Beginning at approximately 22–24 hpf, two populations of cells could be distinguished by staining with *l-pl*, *c-fms*, *mpo*, and *lys C*. One population present in both the tail and yolk sac stained with *mpo* and *lys C* (Fig. 1C) and did not express *l-pl* (Fig. 1A, B) or *c-fms* (Fig. 1D, E). The second population, also present in yolk sac and tail, costained with both *l-pl* and *c-fms* (Fig. 1F), but did not stain with *lys C* or *mpo* (Fig. 1D, E). We conclude that the cells costaining with *l-pl* and *c-fms* are likely macrophages given that *c-fms* is expressed specifically in macrophages in mammals<sup>21</sup> and characterization of macrophages in zebrafish has correlated the movement of these macrophages on video microscopy with the positions of *l-pl* (+) cells by RNA *in situ* hybridization.<sup>10</sup>

*mpo* expression has been demonstrated in adult zebrafish granulocytes by *in situ* hybridizations in kidney sections.<sup>9</sup> Thus, the *mpo* (+)/*lys C* (+) population likely marks granulocytes in embryos. While *mpo* and *lys C* staining was largely coincident, prior to circulation (between 21 somites and 24 hpf) there was a population of *mpo*-staining cells that did not express *lys C*. Single *mpo*-expressing cells were in the ICM only (Fig. 2A), while double-staining *mpo* (+)/*lys C* (+) cells were only present over the yolk sac (Fig. 2B). The population of *mpo* (+)/*lys C* (–) cells in the ICM did not costain with *gata1* (Fig. 2C) and was therefore clearly distinct from erythroid progenitors. In mammals, myeloperoxidase is a primary granule protein, while lysozyme is found in both primary and secondary granules. We therefore postulate that



**FIG. 1.** Double *in situ* hybridization with myeloid markers. (A–F) 28 hpf embryos, lateral views of the tail, with embryos oriented with the head to the left. Double *in situ* hybridizations were performed with dual fluorescent markers, as indicated. Photographs taken with each filter were overlaid using Adobe Photoshop and are shown in (A–F). In (A1) and (A2), individual pictures of an *in situ* hybridized embryo show signal from *lys C* taken using the rhodamine filter (A1) or signal from *l-pl* using the FITC filter (A2). There is no “bleed-through” of signal seen with each filter. (A) is the merged photo using (A1) and (A2). (A), (B), (D), and (E) signals are completely nonoverlapping (white arrows and arrowheads), while in (C) and (F), overlapping signals result in yellow color (white arrows).

the single *mpo*–staining population may represent an earlier step in granulocyte maturation prior to *lys C* expression.


In a previous work we identified a C/ebp family member expressed only in myeloid cells, which we called *c/ebp1*.<sup>17</sup> *c/ebp1* does not have an ortholog in mammals, but has an identified ortholog in at least one other fish species (GenBank accession no. AB049814). We have shown previously that a subset of cells expressing *l-pl* coexpress *c/ebp1*.<sup>17</sup> To determine whether the *mpo/lys C* doubly positive population expressed *c/ebp1*, two-color staining *in situ* hybridizations were performed at 28 hpf with *c/ebp1* and *lys C*. Two-color staining demonstrated coexpression of *c/ebp1* with a subset of *lys C*–expressing cells in the tail (Fig. 2D)

and yolk sac (data not shown). Thus, expression of *c/ebp1* occurs in a subset of the cells of both the macrophage and granulocyte lineages.

*Macrophage development and granulocyte development are differentially affected in pu.1 MO–injected embryos*

To examine the requirement for Pu.1 in zebrafish primitive myeloid development, *pu.1* was targeted in zebrafish embryos using MOs recognizing the *pu.1* translation initiation site (*pu.1* init) or the exon 5 splice donor site (*pu.1* ex 5), which is the most proximal exon to the Ets domain, required for Pu.1 function.

To examine the efficacy of the *pu.1* ex 5 MO, we analyzed splice products from *pu.1* ex 5



**FIG. 2.** Double *in situ* hybridization with myeloid markers and erythroid marker. (A–D) Double *in situ* hybridizations with fast red colorimetric reaction and BM-Purple (Roche) color reaction with probes as marked. Twenty-two hpf embryos are shown in (A–C) in lateral views, and a 28 hpf embryo is shown in (D) in lateral view. (A) ICM of embryo double stained with *mpo* (red) and *lys C* (purple). (B) Yolk sac of embryo shown in (A) shows *lys C* staining. *mpo* staining is coincident with *lys C*, with no cells staining with red only. (C) Tail of embryo double stained with *mpo* (red) and *gata1* (purple). Cells staining only with *mpo* are shown by the black arrow. The *mpo*-staining cells are distinct from the *gata1* (+) erythroid population. (D) Tail of embryo stained with *c/ebp1* (red) and *lys C* (purple). Cells expressing both *c/ebp1* and *lys C* are marked with a white arrow, while cells expressing only *lys C* are marked with a black arrow.


MO-injected embryos. RNA at 21 somites was harvested from *pu.1* ex 5 MO-injected and *pu.1* ex 5-misinjected embryos. Polymerase chain reaction (PCR) primers spanning the exon 5 splice donor site were used to amplify *pu.1* splice products (Fig. 3A). Three products were detected from RNA recovered from *pu.1* ex 5 MO-injected samples, and sequencing revealed that each product was distinct from the wild-type product amplified from *pu.1* ex 5-misinjected or uninjected embryos (Fig. 3A, B). There were three splice variants utilizing different cryptic splice donors and either the exon 6 splice acceptor or a cryptic acceptor (Fig. 3B, C). Each of the products resulted in a predicted translation product lacking the highly conserved Ets-DNA binding domain (Fig. 3C). Thus, all products would be expected to result in non-functional, prematurely truncated proteins. There was no wild-type product detected.

Injection of *pu.1* init (data not shown) or *pu.1* ex 5 (Fig. 4) resulted in complete loss of *l-pl* in 86% of embryos ( $n = 82$ ) compared to animals injected with a control, mismatch MO, in which 100% of embryos expressed *l-pl* ( $p < 0.001$ ) (Fig. 4A, B). There was also loss of myeloid *c-fms* staining in 100% of injected embryos ( $n = 38$ ) (Fig. 4D) compared to controls, which all stained

over the yolk sac for *c-fms* ( $n = 30$ ;  $p < 0.001$ ) (Fig. 4C). Expression of *c-fms* in previously described nonhematopoietic pigment cells/neural crest cells on the dorsum of the tail<sup>19</sup> was unaffected (Fig. 4C, D; arrowheads). Control embryos injected with equal amounts of the negative control MO, *pu.1* ex 5 mis (Fig. 4A, C), or *pu.1* init mis (data not shown) did not affect staining with *l-pl* or *c-fms*. The costaining results combined with the *pu.1* MO results demonstrated that there was loss of macrophage development in the absence of Pu.1.

While injection of either init or ex 5 *pu.1* MO resulted in complete loss of *l-pl* and *c-fms* staining, expression of *mpo* and *lys C* was unaffected in *pu.1* MO-injected embryos (Fig. 4E–H) in three independent experiments. Only when a combination of the two MOs was injected at a maximal concentration of 0.375 mM *pu.1* init and 0.025 mM *pu.1* ex 5, was there loss or severe reduction of *mpo* expression in 92% of embryos ( $n = 38$ ) and loss or severe reduction in *lys C* expression in 67% of embryos ( $n = 45$ ). Injection of higher doses of the combination was toxic, resulting in morphologic abnormalities and lethality (data not shown).

To determine whether the phenotypic changes seen with the MO injections were due to



**FIG. 3.** RT-PCR with mRNA from *pu.1* MO-injected embryos demonstrates aberrant splice products. **(A)** 2% agarose gel electrophoresis with water control (H<sub>2</sub>O), mRNA from uninjected embryos (uninj), *pu.1* ex 5 mis embryos (mis), and *pu.1* ex 5 MO embryos (ex5 MO). Three aberrant splice products were amplified, designated 1, 2, and 3. PCR products were subcloned and sequenced. All products were different than the product amplified from uninjected and mis controls. **(B)** Schematic showing *pu.1* exon 5 and exon 6. PCR primer locations are indicated by black arrow, and the region targeted by the exon 5 MO is shown. The cryptic splice sites are drawn and labeled 1, 2, and 3 as labeled in the agarose gel in **(A)**. **(C)** A region of DNA at the 3' end of exon 5 and the 5' end of exon 6 of *pu.1* is shown. The predicted translations for the splice products 1-3 all result in truncated products, with complete loss of the Ets domain encoded by exon 6 (shown with horizontal shading).

specific loss of Pu.1, rescue experiments with *pu.1* mRNA were performed. mRNA synthesized *in vitro* from *pu.1* cDNA will not be recognized by the ex 5 MO since the splice donor site is absent in normally spliced mRNA. Injection of *pu.1* ex 5 MO (0.1 mM) with *pu.1* mRNA (50 pg) resulted in rescue of *l-pl* expression in 79% of embryos ( $n=85$ ) compared to *l-pl* expression observed in only 13% of embryos injected with MO alone ( $p < 0.001$ ) (Fig. 5A, B).


*c/ebp1* is required for *lys C* expression

To evaluate the function of the transcription factor C/ebp1 in myeloid development, we used two translation initiation site MOs designated *c/ebp1.1* and *c/ebp1.2*. Injection of either MO alone or the combination resulted in significant reduction or absence of *lys C* expression by 24 hpf in 85% of embryos ( $n=79$ )

compared to controls in which *lys C* expression was positive in 100% of embryos ( $n=32$ ) (Fig. 6E, F). In contrast, *l-pl* expression and *mpo* expression were unaffected (Fig. 6A-D). Further, expression of *c/ebp1* itself was significantly reduced or absent in 60-80% of embryos in three independent experiments (Fig. 6G, H), consistent with a model in which C/ebp1 autoregulates its own expression.

*c/ebp1* mRNA (50 pg) lacking the 5' untranslated region recognized by both MOs was co-injected with each MO to assess rescue. Rescue was incomplete, with *lys C* expression in 68% of embryos coinjected with MO and mRNA ( $n=25$ ) compared to expression of *lys C* in 15% of embryos injected with MO alone ( $n=79$ ) ( $p < 0.001$ ). Injection of higher concentrations of mRNA resulted in gross morphologic abnormalities. It is likely that due to the highly conserved bZIP domain of *c/ebp1*, which contains






**FIG. 4.** Injection of ex 5 *pu.1* MO results in loss of *l-pl* and *c-fms* expression. All embryos are 28 hpf and are shown in lateral view with head to the left. Embryo shown is representative of all embryos under specified condition. (A, C, E, and G) *pu.1* ex 5 mis MO-injected embryos (ctrl MO). (B, D, F, and H) *pu.1* ex 5 MO-injected embryos (*pu.1* MO). *In situ* hybridizations were performed with the following markers: (A, B) *l-pl*, (C, D) *c-fms*, (E, F) *mpo*, and (G, H) *lysC*. In (C), black arrows indicate myeloid-specific *c-fms* cell staining, and in (C) and (D), black arrowheads show neural crest-derived pigment cell *c-fms* staining.


the dimerization and DNA binding regions, widespread ectopic expression of *c/ebp1* may activate many genes controlled by the other C/ebp family members. In support of this speculation, in previous work it was also not possible to inject *gata1* mRNA without encoun-

tering toxicity, also likely due to ectopic activation of many Gata-responsive genes.<sup>8</sup>

To confirm the results of the *c/ebp1* MO knockdown, a  $\gamma$ -ray deletion mutant, c1054, which has a deletion in the distal portion of linkage group 24 (M.E. Halpern and A. Fritz,



**FIG. 5.** Rescue of *l-pl* expression by *pu.1* mRNA. Lateral views at 24 hpf are shown, with heads to the left. Embryos were injected with *pu.1* ex 5 MO. Approximately 50 pg negative control mRNA was injected in (A) and 50 pg of *pu.1* mRNA was coinjected in (B). Rescue of *l-pl* expression is shown.



**FIG. 6.** Embryos injected with *c/ebp1* MOs demonstrate absence of *lys C* and *c/ebp1* expression. All embryos are shown in lateral view with head to the left. (A, C, E, and G) *c/ebp1* mis 1 MO-injected embryos (Ctrl MO). (B, D, F, and H) *c/ebp1* MO-injected embryos. *In situ* hybridizations were performed with the following markers: (A, B) *l-pl*, (C, D) *mpo*, (E, F) *lys C*, and (G, H) *c/ebp1*. (G, I) Black arrows indicate expression of the indicated marker in the tail of control embryos (E, G) with minimal staining in *c/ebp1* MO-injected embryos (F, H). White arrowheads indicate staining in yolk sac.

unpublished data), where *c/ebp1* was previously mapped,<sup>17</sup> was examined. We analyzed the deleted region in this mutant by amplification from c1054 genomic DNA with primers within *c/ebp1* and flanking markers. These data showed that the deleted region occurred distal to 64.5 cM and spanned at least 71–72.1 cM, including deletion of *c/ebp1* (Fig. 7A, B). While multiple genes are likely included in the deleted region, the loss of *c/ebp1* provided an opportunity to confirm the MO results in homozygous c1054 mutant embryos.


The mutant embryos displayed normal expression of the macrophage marker *c-fms* (*n* = 11) (Fig. 7C, D) and the granulocyte marker *mpo* (*n* = 17) (Fig. 7E), but had little or no expression of *lys C* (*n* = 23) (Fig. 7F), confirming the findings in the *c/ebp1* MO-injected embryos. Thus, in the absence of *C/ebp1* expression, embryos displayed normal *l-pl*, *c-fms*, and *mpo* expression, allowing us to draw the conclusion that macrophages and granulocytes were present,

but either did not express *lys C* or lacked the granules containing *lys C*.

**Discussion**

The use of the zebrafish for dissection of developmental pathways has gained prominence over the past decade. While many mutants affecting erythroid development have been isolated, few mutants with myeloid defects have been identified.<sup>22</sup> Identification of genes expressed in myeloid cells has now allowed the development of myeloid-specific mutagenesis screens, but a detailed understanding of the normal myelopoietic pathway is still lacking.

An issue of great importance to these analyses is the comparison of primitive myeloid development in the zebrafish to the myeloid processes that occur in higher vertebrates. In zebrafish, both granulocytes and macrophages develop between 21 somites (19.5 hpf) and



**FIG. 7.** Deletion mutant lacking *c/ebp1* has loss of *lys C*. (A) 2% agarose gel with products amplified from genomic DNA. *c/ebp1* primers amplified a product from wild-type (WT) fish genomic DNA, but not from the c1054 deletion mutant. *c/ebpd* primers amplified product from both WT and c1054 deletion mutant. (B) Linkage group 24 map showing relative positions of *c/ebp1* and *c/ebpd*. To the right of the map are shown (+) signs for DNA present in the c1054 mutant, including *c/ebpd* and z9325 (data not shown). The (-) signs indicate DNA that is absent in the deletion mutant, z20051 (data not shown), and *c/ebp1*. (C) Wild-type sibling (WT sib) at 24 hpf shows expression of *c-fms*. (D) c1054 deletion homozygote at 24 hpf is stunted in appearance, but shows normal staining with *c-fms*. (E, F) 48 hpf c1054 deletion homozygotes are shown at 24 hpf in lateral position. While they have deformities due to the deletion in linkage group 24, staining with (E) *mpo* is easily visible (shown by arrows), while there was no staining with (F) *lys C*.

3 days postfertilization (dpf), during the primitive wave of hematopoiesis.<sup>9,11</sup> The great advantage of zebrafish is the ability to analyze these early developmental events. However, it is unclear how primitive myeloid development in the zebrafish compares to primitive macrophage and, more importantly, definitive myeloid development in higher vertebrates.

Our studies reveal that two distinct myeloid cell types can be distinguished in primitive myelopoiesis by whole-mount RNA *in situ* hybridization. The *mpo/lys C* double-staining population labels the neutrophil/heterophil population. In mammals, lysozyme expression has been documented in both granulocytes and macrophages. However, an *in vivo* tagging study, using a *Lysozyme* promoter to drive green fluorescent protein (GFP) expression in mice, demonstrated that GFP was most highly expressed in granulocytes, with much lower expression in myelocyte progenitors and monocytic cells.<sup>23</sup> Our findings are consistent

with that work, showing that lysozyme is most highly expressed in granulocytes.

The *l-pl* (+) population in zebrafish has been previously identified as a macrophage population based on correlation of video microscopy findings and *l-pl* (+) cells by RNA *in situ* hybridization.<sup>10,20</sup> In humans, *L-PL* is expressed in granulocytes, monocytes/macrophages, lymphocytes, and natural killer cells, and is frequently expressed in both hematopoietic and nonhematopoietic malignant cells.<sup>24</sup> In contrast, *C-FMS*, encoding the macrophage colony-stimulating factor receptor, is expressed specifically in macrophages.<sup>25</sup> The coexpression of *c-fms* and *l-pl*, combined with previous work correlating live macrophage movements with *in situ* findings,<sup>10,20</sup> demonstrates that the *l-pl*-expressing cells are likely the monocyte/macrophage population.

We used two different MOs recognizing *pu.1* to assess Pu.1 ablation in zebrafish. Either MO singly resulted in complete loss of *l-pl* and *c-fms*



expression, while *mpo* expression and *lys C* expression were maintained, consistent with a specific loss of the macrophage lineage. When both MOs were injected together at the highest dosage possible without nonspecific toxicity, a significant loss of *mpo* and *lys C* expression could be achieved. These data suggest that a differential threshold level of Pu.1 is needed for macrophage development and granulocyte development.

A number of studies in mammals have identified graded requirements of Pu.1 for development of hematopoietic lineages. *In vivo*, two independent *Pu.1* null mouse models have been characterized.<sup>26,27</sup> In both, development of monocyte/macrophages was deficient, while effects on neutrophil development were more varied. Additional work with both models showed that granulocyte commitment and early gene expression, including expression of *Mpo*, occurred in the absence of *Pu.1*.<sup>28–30</sup> However, formation of terminally differentiated, functional neutrophils did not occur without *Pu.1*.

Studies in tissue culture have demonstrated that higher levels of Pu.1 are required for macrophage development than for granulocyte<sup>31</sup> or B-cell development.<sup>32</sup> Our work demonstrates a definite requirement for *pu.1* in macrophage development, consistent with both mouse models and *in vitro* studies. Granulocytes were able to develop in the zebrafish with very low levels of Pu.1 in our studies.

Recent work using a single *pu.1* initiation MO in zebrafish embryos demonstrated loss of both macrophage and granulocyte development with a single initiation site MO.<sup>33</sup> It is possible that the differences between our findings and those of Rhodes *et al.*<sup>33</sup> may be due to greater Pu.1 knockdown using their MO. Interestingly, the translation initiation *pu.1* MO used by Rhodes *et al.*<sup>33</sup> does not target the first initiation ATG as did our init MO, but rather the fifth in-frame ATG. It is possible that translation occurs from some of these more downstream in-frame ATGs, which might have resulted in continued protein expression with our translation initiation site MO.


Our analysis of the function of C/ebp1 demonstrated a role either in expression of *lys C* or in myeloid development downstream of *mpo*, but upstream of *lys C*. *c/ebp1* is a myeloid-specific *c/ebp* without a mammalian ortholog.<sup>17</sup>

While orthologs for C/EBPA and C/EBPB have been identified in the zebrafish, a zebrafish ortholog for C/EBPE has not been identified in library screens<sup>16</sup> or analysis of the available genetic databases (S.E. Lyons, unpublished results).

We have postulated that C/ebp1 may perform an analogous function with C/EBPε. In humans and mice, C/EBPε is required for expression of secondary granule genes, as shown both by mouse gene ablation studies<sup>34–36</sup> and by the naturally occurring human disorder due to mutations in C/EBPε, neutrophil-specific granule deficiency.<sup>35,37,38</sup> Myeloperoxidase is an enzyme of primary granules, while lysozyme is an enzyme found in both primary and secondary granules.<sup>39,40</sup> Additional secondary granule proteins have not yet been identified in zebrafish. Our finding of *mpo* expression preceding *lys C* expression in cells in the ICM suggests that these cells may be earlier myeloid progenitors. The isolated loss of *lys C* expression after C/ebp1 ablation is consistent with a role for C/ebp1 in terminal myeloid differentiation. We can hypothesize that C/ebp1 may regulate *lys C* or may act upstream of secondary granule formation in granulocytes. The assessment of C/ebp1 function in zebrafish myeloid development suggests that it may play a functionally conserved role with mammalian C/EBPε.<sup>41</sup>

Our data show that primitive myeloid development in zebrafish results in at least two myeloid lineages, distinguishable by multiple markers in RNA *in situ* hybridization. Using *pu.1* and *c/ebp1* MOs, we have begun to construct the developmental pathways of primitive myeloid development in the zebrafish (Fig. 8). The function of Pu.1 appears to be highly conserved from mammalian definitive myelopoiesis to zebrafish primitive myelopoiesis. The functions of C/ebp1 may be conserved with mammalian C/EBPε.

These studies demonstrate that zebrafish primitive myeloid development can be used as a model system with direct relevance to human myeloid lineage development. They also reveal the complexity of the myeloid pathway, and the need to tailor mutagenesis screens to identify myeloid mutants. The choice of the myeloid-specific marker used in a mutagenesis screen will determine the genes and specific pathways that will be identified. Identification and characterization of mutants with defects in myeloid



**FIG. 8.** Schematic of primitive myelopoiesis in zebrafish. A proposed developmental pathway for myelopoiesis in zebrafish embryos is shown with the transcription factors Pu.1 and C/ebp1 placed in the pathway. Higher levels of Pu.1 are needed for macrophage development, while low levels are sufficient for granulocyte development, similar to the gradient required in mammalian hematopoiesis. C/ebp1 is shown upstream of secondary granule formation or regulating *lys C* expression in granulocyte development.

marker expression has the potential to identify genes encoding direct upstream regulators of myeloid proteins and effectors of lineage-determination decisions. Future studies of zebrafish embryonic myelopoiesis will greatly enhance our understanding of the myeloid developmental pathway in vertebrates.

## Materials and Methods

### *Zebrafish maintenance and breeding*

Zebrafish were raised and maintained as described previously,<sup>42</sup> with EK strain wild-type fish used for all studies. Embryos older than 24 hpf were treated with 0.003% 1-phenyl-2-thiourea (Sigma, St. Louis, MO) to inhibit pigment formation.

### *Whole-mount RNA in situ hybridization*

Embryos were collected and whole-mount *in situ* hybridization was performed as previously described<sup>17</sup> with minor modifications. Embryos older than 24 hpf were treated with proteinase K treatment at 10  $\mu$ g/mL for 5 min, embryos at 2 dpf with 20  $\mu$ g/mL for 20 min, and embryos at 3–4 dpf with 100  $\mu$ g/mL for 20 min. Hybridization with probes and the subsequent washes were all performed at 60°C.

Antisense RNAs for *in situ* hybridization were prepared as previously reported for *lys C*,<sup>18</sup>

*mpo*,<sup>9</sup> *l-pl*,<sup>10</sup> *c-fms*,<sup>19</sup> *gata1*,<sup>13</sup> and *c/ebp1*.<sup>17</sup> Probes were synthesized with digoxigenin (DIG)-labeled uridine triphosphates (UTPs) according to the manufacturer's instructions (Roche, Basel, Switzerland) or with fluorescein (FLUOR)-labeled UTPs in the case of double staining.

For two-color staining, *in situ* hybridization was performed as previously described.<sup>17</sup> For fluorescence two-color staining, embryos were hybridized with both DIG-labeled and FLUOR-labeled probes followed by posthybridization incubation with anti-DIG-alkaline phosphatase and anti-FLUOR horseradish peroxidase (HRP) antibodies.<sup>43,44</sup> Color/fluorescent staining was performed with Fast Red (Roche), which formed a color precipitate that is also visible under fluorescence using a rhodamine filter. The HRP-conjugated antibody results in fluorescence detectable with a fluorescein isothiocyanate (FITC) filter using the tyramide signal amplification (TSA)-biotin system (Perkin-Elmer, Waltham, MA). Embryos were visualized on a Leica MZFLIII dissecting microscope and photographed with a Coolsnap digital camera.

### *MO microinjection*

Embryos used for microinjection were obtained from breeding wild-type EK strain zebrafish. The following MOs were created by GENE TOOLS, LLC (Philomath, OR; www.Gene-Tools.com). Lower-case letters designate mismatches, and underscore marks initiation ATG.

*pu.1* init (initiation site MO): 5'-CCTCCATTCTGTACGGATGCAGCAT-3'

*pu.1* init mis (initiation site mismatch): 5'-CgTCgATTCtTACGGATgAGgAT-3'

*pu.1* ex 5 (exon 5 splice MO): 5'-GGTCTTTCTCCTTACCATGCTCTCC-3'

*pu.1* ex 5 mis (exon 5 mismatch MO): 5'-GGTgTTgTCCtTAgCATcCTgTCC-3'

*c/ebp1* 1 (initiation MO 1): 5'-CACCGACATGGCTGTGTGTTGAGCT-3'

*c/ebp1* 2 (initiation MO 2): 5'-TGCTGAACtTACTCGATCTCGTCC-3'

*c/ebp1* mis 1 (init 1 mismatch): 5'-CAgCGAgATGggTGTGTcGAcCT-3'

*c/ebp1* mis 2 (init 2 mismatch): 5'-TcCTcAACTCTAgTCGATCTgGTgC-3'

MOs were injected in volumes of approximately 2 nL at concentrations ranging from 0.05 to 1.0 mM (total quantities injected were

approximately 1–20 ng). For each MO or MO mix, injection concentrations were titrated to determine the maximal injectable dose with minimal nonspecific morphologic abnormalities. MO concentrations injected were as follows: *pu.1* init, 0.75 mM; *pu.1* ex 5, 0.1 mM; *pu.1* init/ex 5, 0.375 mM/0.025 mM; *c/ebp1* init 1/2, 0.25 mM each. The same concentrations of mismatch were used for each corresponding MO. Microinjections were performed according to published protocols<sup>42</sup> using a pneumatic picopump (World Precision Instruments, Sarasota, FL). All results were obtained in at least three independent experiments with at least 20 embryos/MO condition.

#### Analysis of mRNA splice products

After injection of embryos with *pu.1* ex 5 or ex 5 mis MOs, embryos were collected into Trizol (Invitrogen, Carlsbad, CA) at the 21 somite stage. RNA was isolated according to manufacturer's instructions. mRNA was used for a reverse transcriptase reaction using random oligonucleotides as primers followed by PCR using the following primers targeting the *pu.1* cDNA between exon 5 and exon 6:

*pu.1* exon 5 forward: 5'-GACATCGGTGTGTTACCTC-3'

*pu.1* exon 6 reverse: 5'-AGCAGGAAGTATACAAGCG-3'.

For analysis of the deleted region of the c1054  $\gamma$ -ray mutant, genomic DNA from a wild-type control and c1054 were amplified with z-marker primers and primers for *c/ebp1* and *c/ebp1d* described previously.<sup>16,17</sup>

#### mRNA rescue

*pu.1* and *c/ebp1* cDNAs were amplified and subcloned into pCS2+<sup>45</sup> digested with *Bam*HI and *Eco*RI. For *c/ebp1*, the forward primer begins amplification at the ATG, removing the 5' untranslated sequence recognized by the *c/ebp* MOs. The forward primers have a *Bam*HI site underlined, and the reverse primers have an *Eco*RI site underlined:

*c/ebp1* forward: 5'-CGGGATCCGGATGTCAGTCTCTGACAACATC-3'

*c/ebp1* reverse: 5'-GCGAATTCTCAGTGCTCCTCAGATG-3'

*pu.1* forward: 5'-CGGGATCCGGATGCTGCATCCGTA CAG-3'

*pu.1* reverse: 5'-GCGAATTCTTACATGTAATGCTTTC TG-3'

Capped mRNA was synthesized using an mMessage RNA synthesis kit (Ambion, Foster City, CA) as previously described.<sup>46</sup>

Embryos were injected at the one-cell stage with appropriate MOs and 50–100 pg of mRNA. Rescue was evaluated by *in situ* hybridization for rescue of hematopoietic marker expression. Embryos injected with 50–100 pg GFP mRNA were used as negative control embryos.

#### Acknowledgments

We greatly appreciate the gift of deletion mutant c1054 genomic DNA and embryos from Andreas Fritz and Marnie Halpern. We thank Dr. Doug Engel for critical reading of the manuscript.

#### References

1. Begley CG, Aplan PD, Davey MP, Nakahara K, Tchorz K, Kurtzberg J, *et al.* Chromosomal translocation in a human leukemic stem-cell line disrupts the T-cell antigen receptor delta-chain diversity region and results in a previously unreported fusion transcript. *Proc Natl Acad Sci USA* 1989;86:2031–2035.
2. Mueller BU, Pabst T, Osato M, Asou N, Johansen LM, Minden MD, *et al.* Heterozygous PU.1 mutations are associated with acute myeloid leukemia. *Blood* 2002;100:998–1007.
3. Pabst T, Mueller BU, Zhang P, Radomska HS, Naravula S, Schnittger S, *et al.* Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. *Nat Genet* 2001;27:263–270.
4. Shimizu R, Kuroha T, Ohneda O, Pan X, Ohneda K, Takahashi S, *et al.* Leukemogenesis caused by incapacitated GATA-1 function. *Mol Cell Biol* 2004;24:10814–10825.
5. Crispino JD. GATA1 in normal and malignant hematopoiesis. *Semin Cell Dev Biol* 2005;16:137–147.
6. Shafizadeh E, Paw BH. Zebrafish as a model of human hematologic disorders. *Curr Opin Hematol* 2004;11:255–261.
7. Brownlie A, Zon L. The zebrafish as a model system for the study of hematopoiesis. Zebrafish mutants point the way to novel genes involved in the generation of vertebrate blood cells. *Bioscience* 1999;49:382–392.
8. Lyons SE, Lawson ND, Lei L, Bennett PE, Weinstein BM, Liu PP. A nonsense mutation in zebrafish *gata1* causes the bloodless phenotype in vlad tepes. *Proc Natl Acad Sci USA* 2002;99:5454–5459.

9. Bennett CM, Kanki JP, Rhodes J, Liu TX, Paw BH, Kieran MW, *et al.* Myelopoiesis in the zebrafish, *Danio rerio*. *Blood* 2001;98:643–651.
10. Herbomel P, Thisse B, Thisse C. Ontogeny and behaviour of early macrophages in the zebrafish embryo. *Development* 1999;126:3735–3745.
11. Lieschke GJ, Oates AC, Crowhurst MO, Ward AC, Layton JE. Morphologic and functional characterization of granulocytes and macrophages in embryonic and adult zebrafish. *Blood* 2001;98:3087–3096.
12. Bahary N, Zon LI. Use of the zebrafish (*Danio rerio*) to define hematopoiesis. *Stem Cells* 1998;16:89–98.
13. Detrich HW, 3rd, Kieran MW, Chan FY, Barone LM, Yee K, Rundstadler JA, *et al.* Intraembryonic hematopoietic cell migration during vertebrate development. *Proc Natl Acad Sci USA* 1995;92:10713–10717.
14. Fisher RC, Scott EW. Role of PU.1 in hematopoiesis. *Stem Cells* 1998;16:25–37.
15. Simon MC. PU.1 and hematopoiesis: lessons learned from gene targeting experiments. *Semin Immunol* 1998;10:111–118.
16. Lyons SE, Shue BC, Lei L, Oates AC, Zon LI, Liu PP. Molecular cloning, genetic mapping, and expression analysis of four zebrafish *c/ebp* genes. *Gene* 2001;281:43–51.
17. Lyons SE, Shue BC, Oates AC, Zon LI, Liu PP. A novel myeloid-restricted zebrafish CCAAT/enhancer-binding protein with a potent transcriptional activation domain. *Blood* 2001;97:2611–2617.
18. Liu F, Wen Z. Cloning and expression pattern of the lysozyme C gene in zebrafish. *Mech Dev* 2002;113:69–72.
19. Parichy D, Ransom D, Paw B, Zon L, Johnson S. An orthologue of the kit-related gene *fms* is required for development of neural crest-derived xanthophores and a subpopulation of adult melanocytes in the zebrafish, *Danio rerio*. *Development* 2000;127:3031–3044.
20. Herbomel P, Thisse B, Thisse C. Zebrafish early macrophages colonize cephalic mesenchyme and developing brain, retina, and epidermis through a M-CSF receptor-dependent invasive process. *Dev Biol* 2001;238:274–288.
21. Tagoh H, Himes R, Clarke D, Leenen PJ, Riggs AD, Hume D, *et al.* Transcription factor complex formation and chromatin fine structure alterations at the murine *c-fms* (CSF-1 receptor) locus during maturation of myeloid precursor cells. *Genes Dev* 2002;16:1721–1737.
22. Hogan BM, Layton JE, Pyati UJ, Nutt SL, Hayman JW, Varma S, *et al.* Specification of the primitive myeloid precursor pool requires signaling through *Alk8* in zebrafish. *Curr Biol* 2006;16:506–511.
23. Faust N, Varas F, Kelly LM, Heck S, Graf T. Insertion of enhanced green fluorescent protein into the lysozyme gene creates mice with green fluorescent granulocytes and macrophages. *Blood* 2000;96:719–726.
24. Lin CS, Park T, Chen ZP, Leavitt J. Human *plastin* genes. Comparative gene structure, chromosome location, and differential expression in normal and neoplastic cells. *J Biol Chem* 1993;268:2781–2792.
25. Woolford J, Rothwell V, Rohrschneider L. Characterization of the human *c-fms* gene product and its expression in cells of the monocyte-macrophage lineage. *Mol Cell Biol* 1985;5:3458–3466.
26. Scott EW, Simon MC, Anastasi J, Singh H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. *Science* 1994;265:1573–1577.
27. McKercher SR, Torbett BE, Anderson KL, Henkel GW, Vestal DJ, Baribault H, *et al.* Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. *EMBO J* 1996;15:5647–5658.
28. Anderson KL, Smith KA, Connors K, McKercher SR, Maki RA, Torbett BE. Myeloid development is selectively disrupted in PU.1 null mice. *Blood* 1998;91:3702–3710.
29. Anderson KL, Smith KA, Pio F, Torbett BE, Maki RA. Neutrophils deficient in PU.1 do not terminally differentiate or become functionally competent. *Blood* 1998;92:1576–1585.
30. Olson MC, Scott EW, Hack AA, Su GH, Tenen DG, Singh H, *et al.* PU.1 is not essential for early myeloid gene expression but is required for terminal myeloid differentiation. *Immunity* 1995;3:703–714.
31. Dahl R, Walsh JC, Lancki D, Laslo P, Iyer SR, Singh H, *et al.* Regulation of macrophage and neutrophil cell fates by the PU.1:C/EBP $\alpha$  ratio and granulocyte colony-stimulating factor. *Nat Immunol* 2003;4:1029–1036.
32. DeKoter RP, Singh H. Regulation of B lymphocyte and macrophage development by graded expression of PU.1. *Science* 2000;288:1439–1441.
33. Rhodes J, Hagen A, Hsu K, Deng M, Liu TX, Look AT, *et al.* Interplay of *pu.1* and *gata1* determines myeloid progenitor cell fate in zebrafish. *Dev Cell* 2005;8:97–108.
34. Gombart AF, Kwok SH, Anderson KL, Yamaguchi Y, Torbett BE, Koeffler HP. Regulation of neutrophil and eosinophil secondary granule gene expression by transcription factors C/EBP $\epsilon$  and PU.1. *Blood* 2003;101:3265–3273.
35. Gombart AF, Koeffler HP. Neutrophil specific granule deficiency and mutations in the gene encoding transcription factor C/EBP(epsilon). *Curr Opin Hematol* 2002;9:36–42.
36. Yamanaka R, Barlow C, Lekstrom-Himes J, Castilla LH, Liu PP, Eckhaus M, *et al.* Impaired granulopoiesis, myelodysplasia, and early lethality in CCAAT/enhancer binding protein epsilon-deficient mice. *Proc Natl Acad Sci USA* 1997;94:13187–13192.
37. Lekstrom-Himes JA, Dorman SE, Kopar P, Holland SM, Gallin JI. Neutrophil-specific granule deficiency results from a novel mutation with loss of function of the transcription factor CCAAT/enhancer binding protein epsilon. *J Exp Med* 1999;189:1847–1852.
38. Gombart AF, Shiohara M, Kwok SH, Agematsu K, Komiyama A, Koeffler HP. Neutrophil-specific granule deficiency: homozygous recessive inheritance of a frameshift mutation in the gene encoding transcription

- factor CCAAT/enhancer binding protein-epsilon. *Blood* 2001;97:2561–2567.
39. Cramer EM, Breton-Gorius J. Ultrastructural localization of lysozyme in human neutrophils by immunogold. *J Leukoc Biol* 1987;41:242–247.
40. Shaft D, Shtalrid M, Berebi A, Catovsky D, Resnitzky P. Ultrastructural characteristics and lysozyme content in hypergranular and variant type of acute promyelocytic leukaemia. *Br J Haematol* 1998;103:729–739.
41. Lekstrom-Himes JA. The role of C/EBP(epsilon) in the terminal stages of granulocyte differentiation. *Stem Cells* 2001;19:125–133.
42. Westerfield M. *The Zebrafish Book: A Guide for the Laboratory Use of Zebrafish (Danio rerio)*, 3rd ed. University of Oregon Press, Eugene, Oregon, 1995.
43. Raymond PA, Barthel LK. A moving wave patterns the cone photoreceptor mosaic array in the zebrafish retina. *Int J Dev Biol* 2004;48:935–945.
44. Barthel LK, Raymond PA. In situ hybridization studies of retinal neurons. In: K. Palczewsk (ed). *Methods in Enzymology-Vertebrate Phototransduction and the Visual Cycle*. Academic Press, Orlando, FL, 2000, pp. 579–590.
45. Turner DL, Weintraub H. Expression of achaete-scute homolog 3 in *Xenopus* embryos converts ectodermal cells to a neural fate. *Genes Dev* 1994;8:1434–1447.
46. Juarez MA, Su F, Chun S, Kiel MJ, Lyons SE. Distinct roles for SCL in erythroid specification and maturation in zebrafish. *J Biol Chem* 2005;280:41636–41644.

Address reprint requests to:  
Susan E. Lyons, M.D., Ph.D.  
2215 Fuller Road  
Room B740  
Ann Arbor, MI 48105  
E-mail: suslyons@umich.edu





**This article has been cited by:**

1. C. Liongue, C. J. Hall, B. A. O'Connell, P. Crosier, A. C. Ward. 2009. Zebrafish granulocyte colony-stimulating factor receptor signaling promotes myelopoiesis and myeloid cell migration. *Blood* **113**:11, 2535-2546. [[CrossRef](#)]
2. Kevin B. Walters, M. Ernest Dodd, Jonathan R. Mathias, Andrea J. Gallagher, David A. Bennin, Jennifer Rhodes, John P. Kanki, A. Thomas Look, Yevgenya Grinblat, Anna Huttenlocher. 2009. Muscle degeneration and leukocyte infiltration caused by mutation of zebrafish fad24. *Developmental Dynamics* **238**:1, 86-99. [[CrossRef](#)]
3. 2007. Recent Papers on Zebrafish and Other Aquarium Fish ModelsRecent Papers on Zebrafish and Other Aquarium Fish Models. *Zebrafish* **4**:4, 297-308. [[Citation](#)] [[PDF](#)] [[PDF Plus](#)]